
The Director, Clinical Site and Trial Operations (CSTO) provides strategic and operational leadership for Immunome’s clinical trials, overseeing all aspects of site-facing trial execution—from planning and initiation through site and trail closeout—ensuring studies are conducted in compliance with regulatory requirements and corporate objectives.
The Director will lead and develop a high-performing CSTO team, partner closely with Clinical Project Delivery on trial delivery, oversee day-to-day vendor management, and establish site-facing best practices to ensure operational excellence. The Director will collaborate with cross-functional stakeholders, including Clinical Development, Regulatory Affairs, Medical Affairs, CMC, and Quality, to ensure the successful execution of Immunome’s clinical trials.
The Director may also lead one or more outsourced trials and/or lead US site management and trial operations activities on mixed model studies where US site management and monitoring is conducted in-house, and ex-US is outsourced.
Responsibilities
Clinical Trial Oversight
Clinical Operations Leadership
Vendor and CRO Management
Quality Assurance and Regulatory Compliance
Cross-Functional Collaboration
Budget and Resource Management
Qualifications
Knowledge and Skills
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish)

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.